Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

Core Insights - AnaptysBio, Inc. is planning to spin off its biopharma operations into a new public company named First Tracks Biotherapeutics in Q2 2026, aiming to enhance value for investors by separating its biopharma assets from its royalty portfolio [2][5][6] - The company reported strong financial results for Q4 2025, with collaboration revenue significantly increasing due to the performance of Jemperli, which achieved $343 million in sales for the quarter [4][12] Spin-off Details - The spin-off is expected to occur as early as late-April 2026, creating two independent publicly traded companies with distinct business focuses [5][6] - First Tracks Biotherapeutics will concentrate on developing innovative immunology therapeutics, including ANB033, which is currently in Phase 1b trials for celiac disease and eosinophilic esophagitis [5][6][11] - AnaptysBio will retain its name and manage financial collaborations, including those with GSK and Vanda Pharmaceuticals [6] Financial Performance - AnaptysBio reported cash and investments of approximately $311 million as of December 31, 2025, down from $420.8 million a year earlier, primarily due to operating expenses and share repurchases [12][13] - Collaboration revenue for Q4 2025 was $108.2 million, a significant increase from $43.1 million in Q4 2024, driven by Jemperli's sales milestones [12][21] - The company achieved a net income of $49.6 million for Q4 2025, compared to a net loss of $21.8 million in the same period of 2024 [12][21] Product Pipeline - ANB033 is currently undergoing a Phase 1b trial for celiac disease and eosinophilic esophagitis, with top-line data expected in Q4 2026 and 2027, respectively [11][12] - Rosnilimab, another product in the pipeline, has completed a Phase 2b trial for rheumatoid arthritis, with further updates anticipated in Q2 2026 [9][14] - The company has also filed a BLA for imsidolimab, targeting generalized pustular psoriasis, with an FDA action date set for December 12, 2026 [7][14]